Cell and gene therapies represent an important area of modern medicine, using living cells or genetic material to address certain diseases. Their manufacturing processes can differ significantly from those used for conventional medicines because biological materials may be sensitive to temperature, handling, contamination, and processing conditions. Quality assurance plays a central role in ensuring that manufacturing activities follow established procedures and that products meet predefined quality standards. It covers the entire production lifecycle, from sourcing starting materials to final product release and distribution. Effective quality systems also help organizations identify manufacturing risks, investigate unexpected results, and maintain reliable records.
Quality assurance, commonly called QA, is a systematic approach to ensuring that manufacturing processes comply with applicable requirements and approved procedures. In cell and gene therapy production, QA works alongside quality control, which focuses on testing materials and products against defined specifications. Together, these functions support product consistency, traceability, and patient safety.
Good Manufacturing Practice (GMP) requirements provide a foundation for controlling production activities. Depending on the product, manufacturing process, and jurisdiction, organizations must follow applicable regulatory standards and guidance. Quality systems should be designed around the therapy's characteristics, manufacturing risks, and intended use.
Key quality assurance activities include:
Document control: Maintaining approved procedures, manufacturing instructions, specifications, and records so that personnel use current information.
Personnel training: Ensuring employees understand their responsibilities, contamination prevention practices, and the procedures relevant to their work.
Material management: Qualifying suppliers and controlling starting materials, reagents, and other components used during manufacturing.
Environmental monitoring: Assessing controlled manufacturing areas for conditions that could increase contamination risks.
Process validation: Establishing documented evidence that manufacturing processes can consistently produce results meeting predefined requirements.
Deviation management: Recording unexpected events, investigating potential causes, and implementing corrective and preventive actions where appropriate.
These activities help establish a controlled manufacturing environment. The specific procedures and acceptance criteria depend on the therapy, process design, and applicable regulatory framework.
Cell and gene therapies present distinct quality challenges because their starting materials may be biologically variable, their manufacturing processes can involve multiple stages, and some products have limited shelf lives. Autologous therapies, which use cells collected from an individual patient, also require reliable systems to maintain the identity of each patient's material throughout processing. Allogeneic therapies, which use cells from a donor, require controls appropriate to donor eligibility, material characterization, and product consistency.
Quality assurance helps coordinate these controls while quality control testing evaluates characteristics such as identity, purity, potency, and safety. Depending on the product, testing may include sterility assessments, endotoxin testing, viability measurements, genetic characterization, or other relevant analytical methods. Not every test applies to every therapy.
Important considerations include:
Identity and traceability: Maintaining clear links between starting materials, production records, finished products, and intended recipients when applicable.
Contamination control: Applying appropriate aseptic processing practices and monitoring measures to reduce microbiological and cross-contamination risks.
Potency assessment: Using suitable methods to evaluate whether a therapy demonstrates its intended biological activity.
Product stability: Establishing appropriate storage conditions, handling requirements, and supported shelf-life limits.
Change control: Assessing proposed changes to equipment, materials, procedures, or facilities before implementation.
Regulatory documentation: Maintaining accurate records that support inspections, product evaluation, and required regulatory submissions.
Regulatory expectations vary by country and product type. Manufacturers must identify the requirements that apply to their operations and keep quality systems aligned with current regulations and relevant guidance. A robust approach includes reviewing trends, investigating recurring problems, and assessing whether corrective actions are effective.
Quality assurance is essential to the controlled production of cell and gene therapies. By combining documented procedures, trained personnel, validated processes, appropriate testing, and effective traceability, organizations can better manage manufacturing complexity and support consistent product quality. Continuous monitoring and risk-based improvements also help maintain compliance as processes and technologies develop.